RTP Mobile Logo
Novel and Emerging Therapeutic Strategies in the Management of Select B-Cell Lymphomas
Released April 2020

Featuring perspectives from Dr Julie M Vose. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia.

    LEARNING OBJECTIVES

    • Review recent therapeutic advances and related FDA authorizations for mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL) and chronic lymphocytic leukemia (CLL), and use this infor-mation to counsel patients regarding protocol and nonresearch therapy.
    • Consider available Phase III efficacy and safety data with novel targeted agents as first-line therapy for patients with treatment-naïve CLL, and use this information to discern how, if at all, these strategies can be optimally integrated into nonresearch care algorithms.
    • Recall the biologic rationale for and ongoing research evaluating the use of chemotherapy-free combinations in the management of newly diagnosed and progressive CLL and MCL to prepare for the potential introduction of these therapies into practical patient care.
    • Develop an understanding of the biologic rationale for and appreciate available efficacy and safety data with chimeric antigen receptor T-cell therapy, and identify patients with relapsed/refractory B-cell cancers for whom this approach may be appropriate.
    • Appraise the FDA approval of brentuximab vedotin as a component of first-line therapy for newly diagnosed classical HL, and assess the current and future impact on routine clinical practice.
    • Describe available and emerging data with other investigational agents and immunotherapeutic strategies currently under evaluation for MCL, DLBCL, HL and CLL, and where applicable, refer eligible patients for trial participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GrandRoundsBCell20/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Presenting Faculty Member

    Julie M Vose, MD, MBA
    Neumann M and Mildred E Harris Professor
    Chief, Division of Hematology/Oncology
    Nebraska Medical Center
    Omaha, Nebraska

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Verastem Inc; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Epizyme, Janssen Biotech Inc, Kite Pharma Inc, Legend Biotech; Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Incyte Corporation, Kite Pharma Inc, Merck, Novartis, Seattle Genetics.

    Project Steering Committee Members

    Bruce D Cheson, MD
    Lymphoma Consultant
    North Bethesda, Maryland

    Advisory Committee: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Dr Reddy’s Laboratories Ltd, Epizyme, Genentech, a member of the Roche Group, Gilead Sciences Inc, Karyopharm Therapeutics, MorphoSys, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, SymBio Pharmaceuticals Limited, TG Therapeutics Inc; Consulting Agreements: Astellas, Karyopharm Therapeutics, MorphoSys, Parexel International Corporation, SymBio Pharmaceuticals Limited; Contracted Research: AbbVie Inc, Adaptive Biotechnologies, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics, TG Therapeutics Inc, Trillium Therapeutics Inc.

    Andrew M Evens, DO, MSc
    Associate Director for Clinical Services
    Rutgers Cancer Institute of New Jersey
    Medical Director, Oncology Service Line
    RWJBarnabas Health
    Director, Lymphoma Program, Division of Blood Disorders
    Professor of Medicine
    Rutgers Robert Wood Johnson Medical School
    New Brunswick, New Jersey

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Epizyme, Seattle Genetics, TG Therapeutics Inc, Verastem Inc; Consulting Agreements: American Society for Radiation Oncology, American Society of Hematology; Contracted Research: Leukemia & Lymphoma Society, National Cancer Institute, National Institutes of Health, ORIEN, Tesaro, A GSK Company.

    Christopher R Flowers, MD, MS
    Chair, Professor
    Department of Lymphoma/Myeloma
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, OptumRx Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Spectrum Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Burroughs Wellcome Fund, Celgene Corporation, Eastern Cooperative Oncology group, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, National Cancer Institute, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Takeda Oncology, TG Therapeutics Inc, V Foundation for Cancer Research; Data and Safety Monitoring Board/Committee: Denovo Biopharma.

    Ann S LaCasce, MD, MMSc
    Program Director, Fellowship in Hematology/Oncology
    Associate Professor of Medicine, Harvard Medical School
    Institute Physician
    Lymphoma Program
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Humanigen Inc; Consulting Agreement: Seattle Genetics; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company; Institutional Research Funding: Celgene Corporation, Forty Seven Inc, Seattle Genetics.

    John P Leonard, MD
    Richard T Silver Distinguished Professor of Hematology and Medical Oncology
    Associate Dean for Clinical Research
    Executive Vice Chair, Joan and Sanford I Weill Department of Medicine
    Weill Cornell Medicine
    New York, New York

    Consulting Agreements: ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Karyopharm Therapeutics, Miltenyi Biotec, Roche Laboratories Inc, Sandoz Inc, a Novartis Division, Sutro Biopharma Inc; Contracted Research: Agios Pharmaceuticals Inc, Celgene Corporation; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company.

    Andrew D Zelenetz, MD, PhD
    Medical Director, Medical Informatics
    Department of Medicine
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Gilead Sciences Inc, MorphoSys; Consulting Agreements: Adaptive Biotechnologies, Amgen Inc, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Novartis, Roche Laboratories Inc, Verastem Inc; Contracted Research: BeiGene, Gilead Sciences Inc, MEI Pharma, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: BeiGene.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Gilead Sciences Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Seattle Genetics.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: April 2020
    Expiration date: April 2021

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):